The EndoSound Vision System reportedly enables providers to convert existing upper gastrointestinal endoscopes into endoscopic ultrasound modalities.
The Food and Drug Administration (FDA) has cleared the EndoSound Vision System (EndoSound), a modality that may help broaden access to endoscopic ultrasound for gastrointestinal diseases.
EndoSound said the EndoSound Vision System (EVS) can be attached to existing upper gastrointestinal endoscopes. While the company noted that 95 percent of endoscopic ultrasound services are performed in hospital settings, it maintained that the “more economical” EVS may allow more use of the technology in ambulatory care settings.
While 95 percent of endoscopic ultrasound services are reportedly performed in hospital settings, EndoSound maintained that its recently FDA-cleared and “more economical” EndoSound Vision System (shown above) may allow more use of the technology in ambulatory care settings.
The EndoSound Vision System, which previously garnered an FDA Breakthrough Device Designation in July 2021, provides detailed gastrointestinal imaging, and also addresses the issue of infections that may occur with endoscope elevators that are difficult to clean, according to EndoSound.
“This (FDA clearance) milestone underscores our commitment to advancing medical technology and improving patient outcomes. With the EVS, we aim to not only enhance the safety of endoscopic procedures but also contribute to expanding access to care for patients worldwide,” noted Stephen Steinberg, M.D., the president and CEO of EndoSound.
(Editor’s note: For related content, see “Endoscopic Ultrasound Biopsy Modality Gets FDA Nod” and “AI-Powered Liver Tumor Ablation Software Leverages CT, MRI and Ultrasound for Real-Time Image Guidance” and “Diagnostic Imaging’s Top Five Ultrasound Content of 2023.”)
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.